57 Results
Sort By:
Published on November 18, 2019
In the largest study of its kind on individuals with sudden cardiac death, researchers from Massachusetts General Hospital and the Broad Institute of MIT and Harvard performed whole-exome sequencing of 600 patients with adult-onset sudden cardiac death matched with 600 controls. They identified 5,178 genetic variants classifying 14 as pathogenic…
Published on October 8, 2019
Among the challenges long faced by diagnostics developers striving to broaden the use of their tests is finding enough patients to generate enough samples, especially for rare or inherited disorders, as well as finding ways of getting paid for that testing. Invitae launched its own solution to those challenges in…
Published on August 16, 2019
Renovacor, a preclinical-stage gene therapy company, has announced the successful completion of an $11 million Series A financing co-led by Novartis Venture Fund, Broadview Ventures, and BioAdvance, which were joined by New Leaf Venture Partners and Innogest Capital. Proceeds from the financing will help advance the company’s first-of-its-kind gene replacement…
Published on July 25, 2019
Invitae said it is offering for free its Detect genetic testing programs for four conditions: Muscular dystrophy, hereditary prostate cancer, familial cardiomyopathy and arrhythmia, and lysosomal storage diseases. The free testing is being offered for conditions where testing is underused, with the goal of leading to earlier diagnosis and treatment,…
Published on March 5, 2019
The National Institutes of Health announced a five-year, $3.1 million grant for Geisinger,a s an extension of its MyCode Community Health initiative to research innovative, genomics-based approaches for the early detection of arrhythmogenic right ventricular cardiomyopathy (ARVC). ARVC is a degenerative heart disease that is responsible for roughly 20 percent…
Published on January 16, 2019
Researchers from the Sanford Burnham Prebys Medical Discovery Institute (SBP) have identified an epigenetic marker and two genes that caused heart failure in the children and grandchildren of fruit flies with high-fat-diet-induced heart dysfunction. Reversing the epigenetic modification or over-expressing the two genes protected subsequent generations from the negative heart…
Published on October 25, 2018
Precision medicine developer MyoKardia said it will partner with 23andMe to create a digital community designed to enable patients to access information and research opportunities in hypertrophic cardiomyopathy (HCM). Through their collaboration, whose value was not disclosed, the companies plan to launch next year a community designed to improve understanding…
Published on August 10, 2018
Researchers at the University of Alabama at Birmingham have described an underlying mechanism that reprograms the hearts of patients with ischemic cardiomyopathy, a process that differs from patients with other forms of heart failure, collectively known as dilated (non-ischemic) cardiomyopathies. This points the way toward future personalized care for ischemic…
Published on July 31, 2018
A genome-wide association study (GWAS) of more than 1,000,000 people has identified 111 loci for risk of developing atrial fibrillation, of which 80 had not been previously implicated in risk for the heart condition. The research was conducted at the University of Michigan and the Norwegian University of Science and…
Published on May 23, 2018
When it comes to the notion of providing whole-genome sequencing to healthy individuals, there are not one, but two elephants in the room: the cost of the sequencing and analysis itself; and whether people, newly armed with specific information about themselves and their own set of specific genetic variants, might…
Published on April 16, 2018
When President Obama announced the Precision Medicine Initiative at the State of the Union in 2015, it recognized more than a decade of work that scientists and medical researchers had already committed to identifying the underlying genetic causes of diseases and specific pathways to treatment. To date, there have been…
Published on July 18, 2017
Agena Bioscience said today it will co-promote its MassARRAY® DX clinical diagnostics technology with HeartGenetics' CE-IVD marked products for cardiovascular testing, through a co-marketing alliance whose value was not disclosed. Agena’s MassARRAY DX, which is also CE-IVD marked, is a non-fluorescent detection platform utilizing mass spectrometry to accurately measure PCR-derived…